Brief: Marker Therapeutics Announces Clinical Program Updates

Marker Therapeutics

08/01/2024 17:54

Jan 8 (Reuters) - Marker Therapeutics Inc  MRKR.O :
    * MARKER THERAPEUTICS INC - STRATEGIC PRIORITIZATION OF
CLINICAL
PROGRAMS WITH FOCUS ON MT-601 IN PATIENTS WITH LYMPHOMA
    * MARKER THERAPEUTICS INC - MULTITAA-SPECIFIC T CELL
THERAPIES
DEMONSTRATE CLINICAL SAFETY AND POSITIVE CLINICAL DATA ACROSS
MULTIPLE INDICATIONS
    * MARKER THERAPEUTICS INC - INTENDS TO FOCUS ON A READY FOR
USE
PRODUCT FROM COMMERCIALLY AVAILABLE LEUKAPHERESIS MATERIAL
    * MARKER THERAPEUTICS INC - WILL DISCONTINUE
PATIENT-SPECIFIC PART
(ARTEMIS) OF AML PROGRAM
    * MARKER THERAPEUTICS: WORKING TO INITIATE CLINICAL STUDY,
EXPECT
1ST PATIENT WITH AML TO BE TREATED WITH MT-401 MANUFACTURED FROM
HEALTHY DONORS IN H2

Source text for Eikon:  ID:nGNXbh68H3 
Further company coverage:  MRKR.O 

 ((Reuters.Briefs@thomsonreuters.com;))